BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) said today that it is implementing numeric naming for its current drug products to differentiate between formulations and create a unique identity for each product. Effective immediately, RegeneRx’s topical gel will be known as RGN-137; its ophthalmic eye drop as RGN-259; and its parenteral (injectable) formulation as RGN-352. The active pharmaceutical ingredient in each of these formulations will be referred to as Tß4 peptide.
